PMID: 18421189Apr 19, 2008Paper

Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus

Internal Medicine
Akiko NagaishiYasuo Kuroda

Abstract

To examine the long-term effects of tacrolimus in steroid-dependent myasthenia gravis (MG) patients. We administered tacrolimus at 3 mg/day to 10 generalized MG patients presented with clinical worsening by a reduction in dose of prednisolone. The effects of tacrolimus were assessed by using the MG activities of daily living (MG-ADL) profile and the post-intervention status criteria provided by the Myasthenia Gravis Foundation of America (PSC-MGFA). Seven patients were able to use tacrolimus without serious adverse effects for 1.0-5.1 years (mean 3.1 years). Further, its administration improved myasthenic symptoms to the level of pharmacologic remission or minimal manifestations of PSC-MGFA in 5 patients and made it possible to discontinue prednisolone administration in 4 of those 5. However, despite improvements caused by tacrolimus, the reduction in dose of prednisolone caused worsening of symptoms in another 2 patients. In addition, blood trough levels of tacrolimus lower than the recommended range were effective to maintain long-term improvements in 2 patients. Administration of tacrolimus induced long-term improvements and enabled replacement of prednisolone in patients with intractable steroid-dependent MG.

References

May 5, 1999·Neurology·G I WolfeR J Barohn
Dec 26, 2001·The Journal of Biological Chemistry·Todd H DaviesEdwin R Sánchez
Feb 27, 2003·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Hiroaki YoshikawaMasahito Yamada
Aug 25, 2004·Current Medical Research and Opinion·Naoki KawaguchiTakamichi Hattori
Feb 18, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·T KonishiT Saida
Nov 26, 2005·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Yasuhiro ShimojimaShu-ichi Ikeda
Apr 25, 2006·Journal of the Neurological Sciences·Masayoshi TadaMasatoyo Nishizawa
Mar 14, 2007·The Neurologist·Takao MitsuiToshio Matsumoto

❮ Previous
Next ❯

Citations

Jan 29, 2010·Surgery Today·Meinoshin OkumuraHiroyuki Shiono
Apr 14, 2009·Hand : Official Journal of the American Association for Hand Surgery·Thomas H Tung
Apr 21, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·G O SkeieUNKNOWN European Federation of Neurological Societies
Aug 17, 2011·Therapeutics and Clinical Risk Management·Sivakumar Sathasivam
Jun 21, 2013·Disability and Rehabilitation·Alberto RaggiRenato Mantegazza
Jun 19, 2012·The Medical Clinics of North America·Donna Graves, Steven Vernino
Dec 21, 2012·Annals of the New York Academy of Sciences·Srikanth Muppidi
Jun 29, 2010·Muscle & Nerve·Ted M Burns
Mar 6, 2012·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Tomihiro ImaiShun Shimohama
May 2, 2009·Journal of Child Neurology·Paul GadientVinay Puri
Apr 30, 2015·Therapeutic Advances in Neurological Disorders·Jennifer L CruzJamie N Brown
Mar 19, 2015·Research in Cardiovascular Medicine·Seyed Mohammad Javad HosseiniAli Sate
Jan 20, 2017·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·T KanaiS Kuwabara
Jun 30, 2019·Yonsei Medical Journal·Yool Hee KimSeung Min Kim
Nov 17, 2020·Autoimmunity Reviews·Agustina M Lascano, Patrice H Lalive
Jan 7, 2022·Muscle & Nerve·Srikanth MuppidiGlenn A Phillips

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.